Higher Performance of QuantiFERON TB Compared to Tuberculin Skin Test in Latent Tuberculosis Infection Prospective Diagnosis
DOI:
https://doi.org/10.6000/1929-6029.2016.05.01.7Keywords:
Tumor necrosis factor-α inhibitors, latent tuberculosis infection, Tuberculin skin test, QuantiFERON-TB Gold In-Tube.Abstract
Background: The Tuberculin skin test (TST) has been used for years in the latent tuberculosis infection (LTBI) diagnosis, but it has, well-documented, low sensitivity and specificity. Interferon-γ release assays (IGRA) has been reported to be more sensitive and specific than TST. Therefore, this study aimed to evaluate the performance of a commercial IGRA, QuantiFERON®-TB Gold In-Tube (QFT-GIT), comparatively to TST in LTBI diagnosis.
Patients and Methods: This study included 238 patients who were candidate for an anti-TNF therapy. The screening for LTBI was performed by both TST and QFT-GIT test for all patients. In order to evaluate the strength of associations, the odds ratios (OR) together with 95% confidence intervals (CI) were calculated. The correlation between QFT-GIT and TST was evaluated using κ statistics.
Results: Sixty-three (26.4%) sera were positive for QFT-GIT with a mean level of IFN-γ of about 1.18 IU/ml, while 81 (34%) patients were positive for TST. Agreement between QFT-GIT and TST was poor (37 QFT-GIT+/TST- and 55 QFT-GIT-/TST+), κ=0.09 (SD=0.065). The positivity of QFT-GIT was not influenced by BCG vaccination or by immunosuppression. Nevertheless, it was significantly associated to both history of an earlier tuberculosis disease (HETD) and its radiological sequel (RS), p=6E-7 and p=1E-8, respectively. Inversely, the TST results were not correlated to either HETD or RS, but the TST positivity was less frequent in immunosuppressed patients (45.5% vs. 73.9%), p=1E-5, OR (95% CI) = 0.29 [0.17-0.52]. Moreover, the extent of both the immunosuppression period and the time elapsed from the last BCG injection was significantly correlated to a lesser TST positivity, p=3E-12 and p=5E-7, respectively. Among the QFT-GIT-/TST+ patients (n=55) whom received an anti-TNF agent without any prophylactic treatment of LTBI, no tuberculosis was detected with a median follow-up of 78 weeks [56-109].
Conclusion: Our study suggests that the QFT-GIT has a higher performance comparatively to TST in the LTBI screening that is unaffected by either BCG vaccination or immunosuppression. Therefore, IGRAs has to replace TST especially in patients who are under consideration for an anti-TNF therapy.
References
Connor V. Anti-TNF therapies: a comprehensive analysis of adverse effects associated with immunosuppression. Rheumatol Int 2011; 31: 327-37. http://dx.doi.org/10.1007/s00296-009-1292-x DOI: https://doi.org/10.1007/s00296-009-1292-x
Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: Different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 2006; 36: 159-67. http://dx.doi.org/10.1016/j.semarthrit.2006.02.001 DOI: https://doi.org/10.1016/j.semarthrit.2006.02.001
World Health Organization. Global Tuberculosis report 2014. WHO/HTM/TB/2014.08 http://www.who.int/tb/publications/ global_report/en/
Chahed MK, Bellali H, Dhouibi S, Ben Alaya N, Zouari B. Tuberculosis control programme in Tunisia: efficacy assessment. Sante 2010; 20: 87-92. DOI: https://doi.org/10.1684/san.2010.0191
Iqbal AZ, Leighton J, Anthony J, Knaup RC, Peters EB, Bailey TC. Cost-effectiveness of using Quantiferon gold (QFT-G)® versus tuberculin skin test (TST) among U.S. and foreign born populations at a public health department clinic with a low prevalence of tuberculosis. Public Health Nurs 2014; 31: 144-52. http://dx.doi.org/10.1111/phn.12083 DOI: https://doi.org/10.1111/phn.12083
Diel R, Loddenkemper R, Nienhaus A. Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis. Chest 2010; 137: 952-68. http://dx.doi.org/10.1378/chest.09-2350 DOI: https://doi.org/10.1378/chest.09-2350
Siturk L. Haut Conseil de la santé publique. Les nouveaux tests de dépistage de la tuberculose. http://213.150.177.30/mn/details_article.php?t=530&a=23335&temp=1&lang=
Kim JH, Cho SK, Han M, Choi CB, Kim TH, Jun JB, et al. Factors influencing discrepancies between the QuantiFERON-TB Gold in Tube test and the tuberculin skin test in Korean patients with rheumatic diseases. Semin Arthritis 2013; 42: 424-32. http://dx.doi.org/10.1016/j.semarthrit.2012.07.001 DOI: https://doi.org/10.1016/j.semarthrit.2012.07.001
Babayigit C, Ozer B, Tacettin O, Ozer C, Duran N, Gocmen O. Performance of QuantiFERON-TB Gold In-Tube test and tuberculin skin test for diagnosis of latent tuberculosis infection in BCG vaccinated health care workers. Med Sci Monit 2014; 20: 521-9. http://dx.doi.org/10.12659/MSM.889943 DOI: https://doi.org/10.12659/MSM.889943
Ramos JM, Robeldano C, Masiá M, Belda S, Padila S, Rodriguez JC, et al. Contribution of interferon gamma release assays testing to the diagnosis of latent tuberculosis infection in HIV-infected patients: A comparison of QuantiFERON-TB gold in tube, T-SPOT.TB and tuberculin skin test. BMC Infect Dis 2012; 12: 169. http://dx.doi.org/10.1186/1471-2334-12-169 DOI: https://doi.org/10.1186/1471-2334-12-169
Matulis G, Jüni P, Villiger PM, Gadola SD. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon γ assay. Ann Rheum Dis 2008; 67: 84-90. http://dx.doi.org/10.1136/ard.2007.070789 DOI: https://doi.org/10.1136/ard.2007.070789
Bartalesi F, Vicidomini S, Goletti D, Fiorelli C, Fiori G, Melchiorre D, et al. QuantiFERON-TB gold and TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J 2009; 33: 586-93. http://dx.doi.org/10.1183/09031936.00107608 DOI: https://doi.org/10.1183/09031936.00107608
García-Gasalla M, Fernández-Baca V, Juan-Mas A, Payeras-Cifre A, Cifuentes-Luna C, Tberner-Ferrer R, et al. Use of Quantiferon-TB-Gold in Tube® test for detecting latent tuberculosis in patients considered as candidates for anti-TNF therapy in routine clinical practice. Enferm Infecc Microbiol Clin 2013; 31: 76-81. http://dx.doi.org/10.1016/j.eimc.2012.06.014 DOI: https://doi.org/10.1016/j.eimc.2012.06.014
Duman N, Ersoy-Evans S, Karadağ Ö, Aşçioğlu S, Şener B, Kiraz S, et al. Screening for latent tuberculosis infection in psoriasis and psoriatic arthritis patients in a tuberculosis-endemic country: a comparison of the QuantiFERON®-TB Gold In-Tube test and tuberculin skin test. Int J Dermatol 2014; 53: 1286-92. http://dx.doi.org/10.1111/ijd.12522 DOI: https://doi.org/10.1111/ijd.12522
Papay P, Eser A, Winkler S, Frantal S, Primas C, Miehsler W, et al. Factors impacting the results of interferon-γ release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2011; 17: 84-90. http://dx.doi.org/10.1002/ibd.21427 DOI: https://doi.org/10.1002/ibd.21427
Lamberti M, Uccello R, Monaco MGL, Muoio M, Feola D, Sannolo N, et al. Tuberculin skin test and Quantiferon test agreement and influencing factors in tuberculosis screening of healthcare workers: a systematic review and meta-analysis. J Occup Med Toxicol 2015; 10: 2. http://dx.doi.org/10.1186/s12995-015-0044-y DOI: https://doi.org/10.1186/s12995-015-0044-y
Johnson JL, Geldenhuys H, Thiel BA, Toefy A, Suliman S, Pienaar B, et al. Effect of isoniazid therapy on QuantiFeron-TB Gold In-Tube responses in adults with positive tuberculin skin test results in a high TB incidence area. Chest 2014; 145: 612-7. http://dx.doi.org/10.1378/chest.13-1232 DOI: https://doi.org/10.1378/chest.13-1232
Guglielmetti L, Mazzaferri F, Cordioli M, Conti M, Lo Cascio G, Concia E, Cazzadori A, et al. Rebound in QuantiFERON-TB Gold In-Tube response after active tuberculosis treatment. J Infect 2015; 70: 96-8. http://dx.doi.org/10.1016/j.jinf.2014.07.007 DOI: https://doi.org/10.1016/j.jinf.2014.07.007
Chiappini E, Bonsignori F, Mangone G, Galli L, Mazzantini R, Sollai S, et al. Serial T-SPOT.TB and quantiFERON-TB-Gold In-Tube assays to monitor response to antitubercular treatment in Italian children with active or latent tuberculosis infection. Pediatr Infect Dis J 2012; 31: 974-7. http://dx.doi.org/10.1097/INF.0b013e31825d0d67 DOI: https://doi.org/10.1097/INF.0b013e31825d0d67
Dyrhol-Riise AM, Gran G, Wentzel-Larsen T, Blomberg B, Haanshuus CG, Mørkve O. Diagnosis and follow-up of treatment of latent tuberculosis; the utility of the QuantiFERON-TB Gold In-tube assay in outpatients from a tuberculosis low-endemic country. BMC Infect Dis 2010; 10: 57. http://dx.doi.org/10.1186/1471-2334-10-57 DOI: https://doi.org/10.1186/1471-2334-10-57
Pollock NR, Kashino SS, Napolitano DR, Sloutsky A, Joshi S, Guillet J, et al. Evaluation of the Effect of Treatment of Latent Tuberculosis Infection on QuantiFERON-TB Gold Assay Results. Infect Control Hosp Epidemiol 2009; 30: 392-5. http://dx.doi.org/10.1086/596606 DOI: https://doi.org/10.1086/596606
Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc 1970; 26: 28-106.
Linh NN, Marks GB, Crawford AB. Radiographic predictors of subsequent reactivation of tuberculosis. Int J Tuberc Lung Dis 2007; 11: 1136-42.
Farhat M, Greenway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis 2006; 10: 1192-204.
Tavast E, Tuuminen T, Pakkanen SH, Eriksson M, Kantele A, Järvinen A, et al. Immunosuppression adversely affects TST but not IGRAs in patients with psoriasis or inflammatory musculoskeletal diseases. Int J Rheumatol 2012; 2012: 381929. http://dx.doi.org/10.1155/2012/381929 DOI: https://doi.org/10.1155/2012/381929
Encinales L, Zuñiga J, Granados-Montiel J, Yunis M, Granados J, Almeciga I, et al. Humoral immunity in tuberculin skin test anergy and its role in high-risk persons exposed to active tuberculosis. Mol Immunol 2010; 47: 1066-73. http://dx.doi.org/10.1016/j.molimm.2009.11.005 DOI: https://doi.org/10.1016/j.molimm.2009.11.005
Laffitte E, Janssens JP, Roux-Lombard P, Thielen AM, Barde C, Marazza G, et al. Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-γ release assay vs. tuberculin skin test. Br J Dermatol 2009; 161: 797-800. http://dx.doi.org/10.1111/j.1365-2133.2009.09331.x DOI: https://doi.org/10.1111/j.1365-2133.2009.09331.x
Pratt A, Nicholl K, Kay L. Use of QuantiFERON TB Gold test as part of a screening programme in patients with RA under consideration for treatment with anti-TNF-α agents: the Newcastle (UK) experience. Rheumatology 2007; 46:
-6. http://dx.doi.org/10.1093/rheumatology/kem064 DOI: https://doi.org/10.1093/rheumatology/kem064
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2016 Tarak Dhaouadi, Imen Sfar, Leila Mouelhi, Raoudha Tekaya, Ines Mahmoud, Jalila Bargaoui, Raoudha Daghbouj, Leila Abdelmoula, Taoufik Najjar, Taieb Ben Abdallah, Yousr Gorgi
This work is licensed under a Creative Commons Attribution 4.0 International License.
Policy for Journals/Articles with Open Access
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work
Policy for Journals / Manuscript with Paid Access
Authors who publish with this journal agree to the following terms:
- Publisher retain copyright .
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work .
